Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
Khaoula Zekri-Nechar, José Barberán, José J Zamorano-León, María Durbán, Alcira Andrés-Castillo, Carlos Navarro-Cuellar, Antonio López-Farré, Ana López-De-Andrés, Rodrigo Jiménez-García, Carlos H Martínez-Martínez
Medicina, doi:10.3390/medicina58111649
Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASAtreated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality.
Data Availability Statement: This study was carried out using an anonymized database provided by Madrid Hospitals Group. Data are from COVID-19-infected patients admitted in their hospital net that they made kindly available to some Spanish researchers within the program: COVID-19 data saves lives in Spain.
Conflicts of Interest: The authors declare that they have no conflict of interest.
References
Alamdari, Afaghi, Rahimi, Tarki, Tavana et al., Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran, Tohoku J. Exp. Med,
doi:10.1620/tjem.252.73Becattini, Agnelli, Schenone, Eichinger, Bucherini et al., Aspirin for preventing the recurrence of venous thromboembolism, N. Engl. J. Med,
doi:10.1056/NEJMoa1114238Berenguer, Ryan, Rodríguez-Baño, Jarrín, Carratalà et al., for the COVID-19@Spain Study. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain, Clin. Microbiol. Infect,
doi:10.1016/j.cmi.2020.07.024Brighton, Eikelboom, Mann, Mister, Gallus et al., Low-dose aspirin for preventing recurrent venous thromboembolism, N. Engl. J. Med,
doi:10.1056/NEJMoa1210384Canoglu, Saylan, Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection, Ann. Saudi Med,
doi:10.5144/0256-4947.2020.462Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet,
doi:10.1016/S0140-6736(20)30211-7Choi, Kim, Kang, The Potential Role of Dyslipidemia in COVID-19 Severity: An Umbrella Review of Systematic Reviews, J. Lipid Atheroscler,
doi:10.12997/jla.2020.9.3.435Clausen, Sandoval, Spliid, Pihl, Perrett et al., SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2, Cell,
doi:10.1016/j.cell.2020.09.033Eikelboom, Hirsh, Weitz, Johnston, Yi et al., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation,
doi:10.1161/01.CIR.0000013777.21160.07Glatthaar-Saalmüller, Mair, Saalmüller, Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study, Influenza Other Respir. Viruses,
doi:10.1111/irv.12421Goligher, Bradbury, Mcverry, Lawler, Berger et al., Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19, N. Engl. J. Med
Gratz, Wiegele, Maleczek, Herkner, Schöchl et al., Risk of Clinically Relevant Venous Thromboembolism in Critically Ill Patients With COVID-19: A Systematic Review and Meta-Analysis, Front. Med,
doi:10.3389/fmed.2021.647917Lawler, Goligher, Berger, Neal, Mcverry et al., Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19, N. Engl. J. Med
Leentjens, Van Haaps, Wessels, Schutgens, Middeldorp, COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year, Lancet Haematol,
doi:10.1016/S2352-3026(21)00105-8Malas, Naazie, Elsayed, Mathlouthi, Marmor et al., Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis, EClinicalMedicine,
doi:10.1016/j.eclinm.2020.100639Martha, Pranata, Lim, Wibowo, Akbar, Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2021.05.016Nikolich-Zugich, Knox, Rios, Natt, Bhattacharya et al., SARS-CoV-2 and COVID-19 in older adults: What we may expect regarding pathogenesis, immune responses, and outcomes, Geroscience,
doi:10.1007/s11357-020-00186-0O'brien, Duncan, Kirsh, Allen, King et al., Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial, Lancet
Pavoni, Gianesello, Pazzi, Stera, Meconi et al., Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action, Thromb. Res,
doi:10.1016/j.thromres.2020.09.013Pranata, Huang, Lim, Wahjoepramono, July, Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression, J. Stroke Cerebrovasc. Dis,
doi:10.1016/j.jstrokecerebrovasdis.2020.104949Qin, Dong, Zhang, Hu, Chen et al., Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era, Thromb. Res,
doi:10.1016/j.thromres.2020.11.020Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area, JAMA,
doi:10.1001/jama.2020.6775Signes-Costa, Núñez-Gil, Soriano, Arroyo-Espliguero, Eid et al., Prevalence and 30-Day Mortality in Hospitalized Patients with COVID-19 and Prior Lung Diseases, Arch. Bronconeumol,
doi:10.1016/j.arbres.2020.11.012Simes, Becattini, Agnelli, Eikelboom, Kirby et al., INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE collaboration, Circulation,
doi:10.1161/CIRCULATIONAHA.114.008828Speir, Yu, Ferrans, Huang, Epstein, Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells, Circ. Res,
doi:10.1161/01.RES.83.2.210Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost,
doi:10.1111/jth.14817Thachil, Tang, Gando, Falanga, Cattaneo et al., ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J. Thromb. Haemost,
doi:10.1111/jth.14810Walz-Cicconi, Weller, Dose-related effect of acetylsalicylic acid on replication of varicella zoster virus in vitro, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.81.16.5223Wijaya, Andhika, Huang, Purwiga, Budiman, The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis, Clin. Epidemiol. Glob. Health,
doi:10.1016/j.cegh.2021.100883Yuan, Chen, Li, Chen, Wang et al., Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease, J. Cell. Mol. Med,
doi:10.1111/jcmm.16198{ 'indexed': { 'date-parts': [[2022, 11, 17]],
'date-time': '2022-11-17T06:16:42Z',
'timestamp': 1668665802322},
'reference-count': 34,
'publisher': 'MDPI AG',
'issue': '11',
'license': [ { 'start': { 'date-parts': [[2022, 11, 15]],
'date-time': '2022-11-15T00:00:00Z',
'timestamp': 1668470400000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that '
'has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric '
'COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization '
'differ in hospital outcome compared to patients without previous ASA therapy. Materials and '
'Methods: An observational retrospective study was carried out using an anonymized database '
'including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals '
'Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 '
'infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = '
'41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher '
'D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, '
'patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than '
'non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < '
'30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In '
'ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular '
'weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase '
'in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of '
'ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days '
'all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels '
'upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected '
'patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase '
'in-hospital < 30 days all-cause mortality.</jats:p>',
'DOI': '10.3390/medicina58111649',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 11, 16]],
'date-time': '2022-11-16T07:27:34Z',
'timestamp': 1668583654000},
'page': '1649',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected '
'Patients',
'prefix': '10.3390',
'volume': '58',
'author': [ {'given': 'Khaoula', 'family': 'Zekri-Nechar', 'sequence': 'first', 'affiliation': []},
{'given': 'José', 'family': 'Barberán', 'sequence': 'additional', 'affiliation': []},
{'given': 'José J.', 'family': 'Zamorano-León', 'sequence': 'additional', 'affiliation': []},
{'given': 'María', 'family': 'Durbán', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alcira', 'family': 'Andrés-Castillo', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-9869-9240',
'authenticated-orcid': False,
'given': 'Carlos',
'family': 'Navarro-Cuellar',
'sequence': 'additional',
'affiliation': []},
{'given': 'Antonio', 'family': 'López-Farré', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5551-5181',
'authenticated-orcid': False,
'given': 'Ana',
'family': 'López-de-Andrés',
'sequence': 'additional',
'affiliation': []},
{'given': 'Rodrigo', 'family': 'Jiménez-García', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Carlos H.',
'family': 'Martínez-Martínez',
'sequence': 'additional',
'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2022, 11, 15]]},
'reference': [ { 'key': 'ref_1',
'doi-asserted-by': 'crossref',
'first-page': '647917',
'DOI': '10.3389/fmed.2021.647917',
'article-title': 'Risk of Clinically Relevant Venous Thromboembolism in Critically Ill '
'Patients With COVID-19: A Systematic Review and Meta-Analysis',
'volume': '8',
'year': '2021',
'journal-title': 'Front. Med.'},
{ 'key': 'ref_2',
'doi-asserted-by': 'crossref',
'first-page': '507',
'DOI': '10.1016/S0140-6736(20)30211-7',
'article-title': 'Epidemiological and clinical characteristics of 99 cases of 2019 novel '
'coronavirus pneumonia in Wuhan, China: A descriptive study',
'volume': '395',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': 'ref_3',
'doi-asserted-by': 'crossref',
'first-page': '2052',
'DOI': '10.1001/jama.2020.6775',
'article-title': 'Presenting Characteristics, Comorbidities, and Outcomes Among 5700 '
'Patients Hospitalized with COVID-19 in the New York City Area',
'volume': '323',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'ref_4',
'doi-asserted-by': 'crossref',
'first-page': '505',
'DOI': '10.1007/s11357-020-00186-0',
'article-title': 'SARS-CoV-2 and COVID-19 in older adults: What we may expect regarding '
'pathogenesis, immune responses, and outcomes',
'volume': '42',
'year': '2020',
'journal-title': 'Geroscience'},
{ 'key': 'ref_5',
'doi-asserted-by': 'crossref',
'first-page': '4',
'DOI': '10.1161/CIRCULATIONAHA.120.047659',
'article-title': 'Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple '
'Potential Mechanisms',
'volume': '142',
'year': '2020',
'journal-title': 'Circulation'},
{ 'key': 'ref_6',
'doi-asserted-by': 'crossref',
'first-page': '1295',
'DOI': '10.1016/S0140-6736(00)02110-3',
'article-title': 'Prevention of pulmonary embolism and deep vein thrombosis with low dose '
'aspirin: Pulmonary Embolism Prevention (PEP) trial',
'volume': '355',
'year': '2000',
'journal-title': 'Lancet'},
{ 'key': 'ref_7',
'doi-asserted-by': 'crossref',
'first-page': '1959',
'DOI': '10.1056/NEJMoa1114238',
'article-title': 'WARFASA Investigators. Aspirin for preventing the recurrence of venous '
'thromboembolism',
'volume': '366',
'year': '2012',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_8',
'doi-asserted-by': 'crossref',
'first-page': '1979',
'DOI': '10.1056/NEJMoa1210384',
'article-title': 'Low-dose aspirin for preventing recurrent venous thromboembolism',
'volume': '367',
'year': '2012',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_9',
'doi-asserted-by': 'crossref',
'first-page': '104949',
'DOI': '10.1016/j.jstrokecerebrovasdis.2020.104949',
'article-title': 'Impact of cerebrovascular and cardiovascular diseases on mortality and '
'severity of COVID-19-systematic review, meta-analysis, and '
'meta-regression',
'volume': '29',
'year': '2020',
'journal-title': 'J. Stroke Cerebrovasc. Dis.'},
{ 'key': 'ref_10',
'doi-asserted-by': 'crossref',
'first-page': '313',
'DOI': '10.1016/j.thromres.2020.09.013',
'article-title': 'Venous thromboembolism and bleeding in critically ill COVID-19 patients '
'treated with higher than standard low molecular weight heparin doses '
'and aspirin: A call to action',
'volume': '196',
'year': '2020',
'journal-title': 'Thromb. Res.'},
{ 'key': 'ref_11',
'doi-asserted-by': 'crossref',
'first-page': '73',
'DOI': '10.1620/tjem.252.73',
'article-title': 'Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major '
'Referral Center in Iran',
'volume': '252',
'year': '2020',
'journal-title': 'Tohoku J. Exp. Med.'},
{ 'key': 'ref_12',
'doi-asserted-by': 'crossref',
'first-page': '1023',
'DOI': '10.1111/jth.14810',
'article-title': 'ISTH interim guidance on recognition and management of coagulopathy in '
'COVID-19',
'volume': '18',
'year': '2020',
'journal-title': 'J. Thromb. Haemost.'},
{ 'key': 'ref_13',
'doi-asserted-by': 'crossref',
'first-page': '13',
'DOI': '10.1016/j.arbres.2020.11.012',
'article-title': 'Prevalence and 30-Day Mortality in Hospitalized Patients with COVID-19 '
'and Prior Lung Diseases',
'volume': '57',
'year': '2021',
'journal-title': 'Arch. Bronconeumol.'},
{ 'key': 'ref_14',
'unstructured': 'World Health Organization (2022, July 10). Coronavirus Disease '
'(COVID-19) Outbreak. Regional Office for Europe. Available online: '
'https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/statements/statement-older-people-are-at-highest-risk-from-covid-19,-but-all-must-act-to-prevent-community-spread.'},
{ 'key': 'ref_15',
'doi-asserted-by': 'crossref',
'first-page': '1525',
'DOI': '10.1016/j.cmi.2020.07.024',
'article-title': 'Characteristics and predictors of death among 4035 consecutively '
'hospitalized patients with COVID-19 in Spain',
'volume': '26',
'year': '2020',
'journal-title': 'Clin. Microbiol. Infect.'},
{ 'key': 'ref_16',
'first-page': '649',
'article-title': 'Platelets and infection—An emerging role of platelets in viral '
'infection',
'volume': '5',
'year': '2014',
'journal-title': 'Front. Immunol.'},
{ 'key': 'ref_17',
'first-page': '85',
'article-title': 'Antiviral activity of aspirin against RNA viruses of the respiratory '
'tract-an in vitro study',
'volume': '11',
'year': '2016',
'journal-title': 'Influenza Other Respir. Viruses'},
{ 'key': 'ref_18',
'doi-asserted-by': 'crossref',
'first-page': '5223',
'DOI': '10.1073/pnas.81.16.5223',
'article-title': 'Dose-related effect of acetylsalicylic acid on replication of varicella '
'zoster virus in vitro',
'volume': '81',
'year': '1984',
'journal-title': 'Proc. Natl. Acad. Sci. USA'},
{ 'key': 'ref_19',
'doi-asserted-by': 'crossref',
'first-page': '210',
'DOI': '10.1161/01.RES.83.2.210',
'article-title': 'Aspirin attenuates cytomegalovirus infectivity and gene expression '
'mediated by cyclooxygenase-2 in coronary artery smooth muscle cells',
'volume': '83',
'year': '1998',
'journal-title': 'Circ. Res.'},
{ 'key': 'ref_20',
'doi-asserted-by': 'crossref',
'first-page': '6',
'DOI': '10.1016/j.ijid.2021.05.016',
'article-title': 'Active prescription of low-dose aspirin during or prior to '
'hospitalization and mortality in COVID-19: A systematic review and '
'meta-analysis of adjusted effect estimates',
'volume': '108',
'year': '2021',
'journal-title': 'Int. J. Infect. Dis.'},
{ 'key': 'ref_21',
'doi-asserted-by': 'crossref',
'first-page': '100883',
'DOI': '10.1016/j.cegh.2021.100883',
'article-title': 'The effects of aspirin on the outcome of COVID-19: A systematic review '
'and meta-analysis',
'volume': '12',
'year': '2021',
'journal-title': 'Clin. Epidemiol. Glob. Health'},
{ 'key': 'ref_22',
'doi-asserted-by': 'crossref',
'unstructured': 'Kulkarni, S., Jenner, B.L., and Wilkinson, I. (2020). COVID-19 and '
'hypertension. J. Renin. Angiotensin Aldosterone Syst., 21.',
'DOI': '10.1177/1470320320927851'},
{ 'key': 'ref_23',
'doi-asserted-by': 'crossref',
'first-page': '435',
'DOI': '10.12997/jla.2020.9.3.435',
'article-title': 'The Potential Role of Dyslipidemia in COVID-19 Severity: An Umbrella '
'Review of Systematic Reviews',
'volume': '9',
'year': '2020',
'journal-title': 'J. Lipid Atheroscler.'},
{ 'key': 'ref_24',
'doi-asserted-by': 'crossref',
'first-page': '1263',
'DOI': '10.1111/jcmm.16198',
'article-title': 'Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 '
'patients with coronary artery disease',
'volume': '25',
'year': '2021',
'journal-title': 'J. Cell. Mol. Med.'},
{ 'key': 'ref_25',
'first-page': '100639',
'article-title': 'Thromboembolism risk of COVID-19 is high and associated with a higher '
'risk of mortality: A systematic review and meta-analysis',
'volume': '29',
'year': '2020',
'journal-title': 'EClinicalMedicine'},
{ 'key': 'ref_26',
'doi-asserted-by': 'crossref',
'first-page': '1062',
'DOI': '10.1161/CIRCULATIONAHA.114.008828',
'article-title': 'INSPIRE Study Investigators (International Collaboration of Aspirin '
'Trials for Recurrent Venous Thromboembolism). Aspirin for the '
'prevention of recurrent venous thromboembolism: The INSPIRE '
'collaboration',
'volume': '130',
'year': '2014',
'journal-title': 'Circulation'},
{ 'key': 'ref_27',
'doi-asserted-by': 'crossref',
'first-page': '1043',
'DOI': '10.1016/j.cell.2020.09.033',
'article-title': 'SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2',
'volume': '183',
'year': '2020',
'journal-title': 'Cell'},
{ 'key': 'ref_28',
'first-page': '19',
'article-title': 'Low molecular weight heparin and 28-day mortality among patients with '
'coronavirus disease 2019: A cohort study in the early epidemic era',
'volume': '198',
'year': '2020',
'journal-title': 'Thromb. Res.'},
{ 'key': 'ref_29',
'doi-asserted-by': 'crossref',
'first-page': '1094',
'DOI': '10.1111/jth.14817',
'article-title': 'Anticoagulant treatment is associated with decreased mortality in '
'severe coronavirus disease 2019 patients with coagulopathy',
'volume': '18',
'year': '2020',
'journal-title': 'J. Thromb. Haemost.'},
{ 'key': 'ref_30',
'doi-asserted-by': 'crossref',
'first-page': 'e524',
'DOI': '10.1016/S2352-3026(21)00105-8',
'article-title': 'COVID-19-associated coagulopathy and antithrombotic agents-lessons '
'after 1 year',
'volume': '8',
'year': '2021',
'journal-title': 'Lancet Haematol.'},
{ 'key': 'ref_31',
'doi-asserted-by': 'crossref',
'first-page': '462',
'DOI': '10.5144/0256-4947.2020.462',
'article-title': 'Therapeutic dosing of low-molecular-weight heparin may decrease '
'mortality in patients with severe COVID-19 infection',
'volume': '40',
'year': '2020',
'journal-title': 'Ann. Saudi Med.'},
{ 'key': 'ref_32',
'doi-asserted-by': 'crossref',
'first-page': '777',
'DOI': '10.1056/NEJMoa2103417',
'article-title': 'Therapeutic Anticoagulation with Heparin in Critically Ill Patients '
'with COVID-19',
'volume': '385',
'year': '2021',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_33',
'doi-asserted-by': 'crossref',
'first-page': '790',
'DOI': '10.1056/NEJMoa2105911',
'article-title': 'Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients '
'with COVID-19',
'volume': '385',
'year': '2021',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_34',
'doi-asserted-by': 'crossref',
'first-page': '1650',
'DOI': '10.1161/01.CIR.0000013777.21160.07',
'article-title': 'Aspirin-resistant thromboxane biosynthesis and the risk of myocardial '
'infarction, stroke, or cardiovascular death in patients at high risk '
'for cardiovascular events',
'volume': '105',
'year': '2002',
'journal-title': 'Circulation'}],
'container-title': 'Medicina',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/1648-9144/58/11/1649/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 11, 16]],
'date-time': '2022-11-16T09:38:26Z',
'timestamp': 1668591506000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/1648-9144/58/11/1649'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 11, 15]]},
'references-count': 34,
'journal-issue': {'issue': '11', 'published-online': {'date-parts': [[2022, 11]]}},
'alternative-id': ['medicina58111649'],
'URL': 'http://dx.doi.org/10.3390/medicina58111649',
'relation': {},
'ISSN': ['1648-9144'],
'subject': ['General Medicine'],
'container-title-short': 'Medicina',
'published': {'date-parts': [[2022, 11, 15]]}}
